Evidence map›Paper›PMID 42443171›Full record

ArticleNature communications2026

Neutrophil myeloperoxidase as a functional biomarker for RSV severity: implications for in vitro therapeutic screening.

Machaela Palor, Tereza Masonou, Elisabeth J Robinson, Wenqing Chen, Samuel Ellis, Laura Buggiotti, Amy I Jacobs, Thomas Benoist, Paolo De Coppi, Jennifer L Rohn and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Machaela Palor *Great Ormond Street Institute of Child Health, University College London, London, UK.
Tereza Masonou *Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0003-3663-8965
Elisabeth J RobinsonDepartment of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
Wenqing ChenGreat Ormond Street Institute of Child Health, University College London, London, UK.
Samuel EllisGreat Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0002-5012-4277
Laura BuggiottiGreat Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0002-7404-7800
Amy I JacobsGreat Ormond Street Institute of Child Health, University College London, London, UK.
Thomas BenoistGreat Ormond Street Institute of Child Health, University College London, London, UK.
Paolo De CoppiGreat Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0002-1659-0207
Jennifer L RohnDivision of Medicine, University College London, London, UK.ORCID 0000-0001-8766-6056
Gabriele PollaraInstitute of Infection, Immunity & Transplantation, University College London, London, UK.ORCID 0000-0001-5772-0322
Mario Cortina-BorjaGreat Ormond Street Institute of Child Health, University College London, London, UK.
Maximillian N J WoodallGreat Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0003-4511-9171
Robert E HyndsEpithelial Cell Biology in ENT Research (EpiCENTR) Group, Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0002-2170-8791
Rosalind L SmythGreat Ormond Street Institute of Child Health, University College London, London, UK.
Samiran RayGreat Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0002-3738-4672
Claire M SmithGreat Ormond Street Institute of Child Health, University College London, London, UK. c.m.smith@ucl.ac.uk.ORCID 0000-0002-8913-0009

Funding

Animal Free Research UK AFR19-20274RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/V006738/1
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infections in infants, yet therapeutics are lacking. The aim of this study was to develop a pre‑clinical model that recapitulates key clinical outcomes in infants with RSV bronchiolitis, such as neutrophil activation and migration into the airways. Peripheral blood neutrophils from infants with severe RSV disease admitted to the Paediatric Intensive Care Unit showed elevated myeloperoxidase (MPO) in children with RSV, compared to age-matched controls. To mechanistically model this response, we established an air-liquid interface (ALI) system incorporating paediatric airway epithelial cells, endothelial cells and neutrophils from adults, to recapitulate the blood-airway barrier. Following RSV infection, with and without treatment with antivirals remdesivir or RSV604, neutrophil migration and activation were assessed using flow cytometry. While both drugs reduced viral load, only RSV604 attenuated MPO expression. This model suggests that MPO could be useful as a readout of therapeutic efficacy. Targeting neutrophil-driven inflammatory pathways may be critical for reducing pathology in infant RSV infection.

Indexed as

NeutrophilsPeroxidaseRespiratory Syncytial Virus InfectionsAdenosine MonophosphateAlanineAntiviral AgentsBiomarkersCell MovementFemaleHumansInfantMaleNeutrophil ActivationRespiratory Syncytial Virus, HumanViral LoadAdenosine MonophosphateAlanineAntiviral AgentsBiomarkersMPO protein, humanPeroxidaseremdesivir

Identifiers

PMID42443171
PMCPMC13365213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.